Depressions with eating disorders: clinical manifestations and therapy [Депрессии с расстройствами пищевого поведения: клинические проявления и терапия]

Depression is a common comorbid diagnosis in patients with eating disorders (EDs). The development of pathogenetic therapy for depression with EDs is far from being completed. The objective of the psychopharmacotherapeutic study was to evaluate the efficacy and tolerability of melatonergic monotherapy with the antidepressant agomelatine (25–50 mg/day at night) for depressions with two ED variants: hyperphagic (n=32) and hypo- and aphagic (n=31) EDs. Patients and methods. The investigation enrolled patients of both sexes, aged 18 to 65 years. The investigators performed clinical psychopathological and experimental psychological studies, as well as psychometric examination using the 21-item Hamilton Depression Rating Scale (HDRS-21), the Clinical Global Impression (CGI), the Supplemental Hospital Offset Payment Program (SHOPP), the Dutch Eating Behavior Questionnaire (DEBQ), and statistical data processing. Results and discussion. There was a significant pronounced antidepressant effect of 6-week agomelatine therapy for depressions occurring with different ED variants both in the pattern of the depressive symptom complex and in that of concurrent with and preceding the latter. At the same time, the efficacy of the drug did not depend on the clinical presentations of the leading hypothymic syndrome, the variants of EDs, and the duration of actual depression. However, by the end of the study period, a larger effect was achieved in the therapy for depressions with the hyperphagic variant of EDs, as well as in patients with EDs manifesting in the pattern of depressive symptom complex. Agomelatine has a favorable tolerance profile. BMI tends to become normal in patients with different variants of EDs during the therapy. The adverse events are transient and/or unclear; they do not require therapy discontinuation. Conclusion. Agomelatine is an effective and relatively safe drug that can be recommended to treat depressions concurrent with EDs in therapeutic dosages for at least 6 weeks. © 2020 Ima-Press Publishing House. All rights reserved.

Medvedev V.E. , Frolova V.I. 1, 5 , Gushanskaya E.V. 1, 5, 2, 6 , Fofanova Yu.S. 3, 7 , Martynov S.E.4, 8 , Zuikova N.L. 1, 5 , Burno A.M. 1, 5 , Nekrasova S.V. 1, 5 , Salyntsev I.V. 1, 5
Ima-Press Publishing House
Номер выпуска
  • 1 Department of Psychiatry, Psychotherapy, and Psychosomatic Pathology, Faculty of Continuing Medical Education, Medical Institute, Peoples’ Friendship University of Russia (RUDN University), Moscow, Russian Federation
  • 2 Psychiatric Clinical Hospital Thirteen, Moscow Healthcare Department, Moscow, Russian Federation
  • 3 Clinical Hospital One, Presidential Administration of the Russian Federation, Moscow, Russian Federation
  • 4 International Institute of Psychosomatic Health, Moscow, Russian Federation
  • 5 Miklukho-Maklai St., Moscow, 117198, Russian Federation
  • 6 27, Stavropolskaya St., Moscow, 109559, Russian Federation
  • 7 Starovolynskaya St., Moscow, 121352, Russian Federation
  • 8 14, Neglinnaya St., Build. 1, Moscow, 107031, Russian Federation
Ключевые слова
Agomelatine; Anorexia; Bulimia; Depression; Eating disorders; Hyperphagia; Hypophagia
Дата создания
Дата изменения
Постоянная ссылка

Другие записи